Evotec
Tobias Bunke has a diverse work experience that spans across various industries. Tobias started their career as a Working Student at HUGO BOSS, where they focused on Business Process Excellence. Tobias then had internships at both Dräger and Daimler AG in the Controlling department. After that, Tobias joined PwC as an Associate in the Transactions department, where they eventually became a Senior Associate. Tobias stayed at PwC until 2019. Following their time at PwC, Tobias moved to Evotec and held several roles, including Project Specialist, PMO Lead, and currently VP Strategic & Transformation Projects in the Global Finance division. Overall, their experience showcases their versatility and expertise in finance, project management, and strategic planning.
Tobias Bunke completed their education as follows:
- From 2015 to 2016, they pursued a Master of Science (M.Sc.) at Maastricht University.
- Between 2011 and 2014, they earned a Bachelor of Science (B.Sc.) from the University of Tübingen.
- In 2013, Tobias briefly studied at The University of Hong Kong, focusing on a Bachelor of Economics & Finance (BEcon&Fin).
Additionally, they obtained the following certifications:
- In 2021, Tobias completed "The Science and Business of Biotechnology" course from MITx on edX.
- In 2020, they became a Certified Valuation Analyst through the European Association of Certified Valuators and Analysts (EACVA).
This person is not in the org chart
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.